Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Conditions
Interventions
NBI-98854
Locations
48
United States
Anaheim, California, United States
Glendale, California, United States
Irvine, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Oakland, California, United States
Start Date
March 1, 2015
Primary Completion Date
March 1, 2017
Completion Date
March 1, 2017
Last Updated
November 30, 2018
NCT07173920
NCT06997198
NCT05859698
NCT06474650
NCT05238701
NCT02198794
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions